Consistent with these findings, we observed that PBRM1 mutations were associated with decreased immune infiltrates in an analysis of nearly 700 patients with ccRCC, and with poor response to ICB-containing therapy. The gene discussed is PBRM1; the disease is nonpapillary renal cell carcinoma.